← Back to patent-cliff list
BW-20507
Tier C — Watch / tradeBW-20507
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：HBsAg, ASGPR
Indications (approved)：Chronic hepatitis B
Regional status
US
-
EU
-
China
Phase II
2025-04-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BW-20507?
Approved indications include: Chronic hepatitis B.
When does the BW-20507 patent expire?
No public expiry year is available for BW-20507 yet; this page updates once verified.
How do I get a quote for BW-20507 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02